Global IP lead

Job Title: Global IP lead Location: Barcelona (Spain), Romania, Bulgaria, other European locations considered Reporting to: Vice-president of portfolio and IP Why This Role Rocks: Be at the heart of innovation in a pharma company blending generics and breakthrough drugs. Own the European IP strategy. Your work directly shapes market access and portfolio success. Work with a dynamic, global team bridging IP, Regulatory, and Business Development. Lead high-stakes patent challenges, oppositions, and new filings. Make your mark! Guide and support team members, contributing to their development and success. Who You Are: European Patent Attorney (or almost there) with 5–10 years in pharma patents. Confident navigating complex European IP landscapes, FTO, SPCs, and exclusivities. Analytical, hands-on, structured. You love solving tough IP puzzles. Fluent in English, curious about other languages, and thrive in multicultural teams. Your Mission: Assess Freedom to Operate and unlock routes to market. Lead oppositions, appeals, and patent lifecycle management in Europe. Protect innovation; spot opportunities, draft new filings, and monitor competitors. Be the trusted IP advisor for Regulatory, Licensing, and Business Development teams. Manage trademarks and brand IP with a strategic mindset. Why You’ll Love It: High-impact role where your decisions matter globally. Opportunity to grow in a fast-paced, international company. Real strategic ownership. Your fingerprints on every key project. About Lotus Lotus is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals. Founded in Taiwan and recognized for its robust R&D and manufacturing platform in Asia, Lotus combines focused in-house capabilities with a network of partners to ensure a competitive advantage through enhanced speed and flexibility. The company delivers a diverse portfolio of high-quality, affordable medicines to markets worldwide.

Location: Catalonia, ES

Posted Date: 10/31/2025